A new diagnostic tool proven to be more effective in the detection
of Barrett’s esophagus and dysplasia than forceps biopsy alone
The WATS3D (Wide Area Transepithelial Sample with 3D Analysis) system provides a significant advance in the routine prevention of the most rapidly growing cancer in the US. WATS3D has been shown to be highly effective in quickly and easily increasing your detection of precancerous abnormality of the esophagus when used as adjunct to standard targeted forceps biopsy.
WATS3D® addresses the sampling limitations of random forceps biopsies by obtaining a unique wide area tissue sample composed of three dimensional microbiopsies. Unlike cytology the WATS3D brush biopsy obtains a transepithelial specimen of the full-thickness esophageal mucosa for computer-assisted 3-dimensional analysis by specially trained GI pathologists.
Patented WATS3D collection instrument quickly and easily expands the tissue area tested, minimizing sampling error.
Computer-assisted 3-Dimensional analysis provides increased accuracy.
Easily fits in the channel of a standard endoscope.
Minimal additional procedure time.
…four quadrant biopsies in Barrett’s esophagus leave significant unsampled mucosa. If dysplasia is missed, both the doctor and the patient have inaccurate information to guide care. WATS increases the likelihood of finding that potentially dangerous dysplasia, and does so quickly and with relatively low cost – something other techniques cannot offer.
Seeking dysplasia in a segment of Barrett’s esophagus is like looking for the proverbial needle in a haystack. Academic centers tend to perform numerous forceps biopsies on each of the high risk patients that they follow. The fact that the brush biopsy with computer-assisted tissue analysis was found to increase detection by over 40% in even these highly experienced esophageal GI specialty centers demonstrates the potential of this technique.
These two large studies demonstrating the same high degree of benefit from addition of the Brush Biopsy in two very different patient populations are extremely convincing. There is no reason not to include this test as part of every upper endoscopy with biopsy, and it will soon be available through all of our member hospitals and GI ambulatory surgery centers.